|
Indian Pediatr 2021;58:
89-90 |
 |
Successful Convalescent Plasma Therapy in a
Child With Severe Coronavirus Disease
|
Sudipta Sekhar Das,* Kaustabh Chaudhuri and Rathindra
Nath Biswas
Department of Transfusion Medicine, Apollo
Gleneagles Hospitals, Kolkata 700 054, India.
Email:
[email protected]
PII: S097475591600259;
Published online: December 01, 2020
|
Most pediatric coronavirus disease (COVID-19) patients are asymptomatic
or have mild to moderate disease and recover within two weeks [1,2]. In
children, severe acute respiratory distress syndrome (ARDS) can occur,
which may progress to toxic shock syndrome. In some affected children
clinical features of Kawasaki disease may be observed [3]. Therapeutics
like antiviral drugs and/or immune modulators available for COVID-19
children have weak recommendations [4]. COVID convalescent plasma (CCP)
has been used successfully in the recent global outbreak for the
treatment of adult patients with COVID-19 [5,6]. We report paediatric
patient who received CCP as a therapeutic option for treatment of severe
COVID-19.
A severely undernourished 13-year-old girl with
fever, cough, sore throat for three days was admitted with severe
respiratory distress and restlessness. On admission, she was febrile,
with tachycardia (146/min), hypotension (90/58 mm Hg) and respiratory
rate of 20/min. The oxygen saturation was 88% on room air.
Nasopharyngeal swab reverse transcriptase – polymerase chain reaction
(RT-PCR) confirmed SARS-CoV-2, and a diagnosis of severe COVID-19 was
made. Child was tried with non-invasive ventilation, which was
subsequently escalated to pressure control mode of mechanical
ventilation. In view of hypotension, cytokine storm was thought of as a
possibility and appropriate fluid resuscitation was done. Arterial
invasive blood pressure monitoring was done, along with use of inotropic
agents like noradrenaline. Bedside echocardiography suggested ejection
fraction of 26%. Child was shifted to a COVID-designated intensive care
unit and started on remdesivir, enoxaparin and antibiotics.
Investigations on day of admission revealed deranged hematological,
biochemical and inflammatory markers. X-ray chest showed
non-homogenous opacities of pneumonitic changes in the mid and lower
zone of both lung fields with right-sided pleural effusion. On day 2 of
admission, the child deteriorated and had worsening septic shock with
arrhythmia (prolonged QTc) and subsequently adrenaline was added.
Mechanical ventilation was continued in view of ARDS with highest
plateau pressure around 28.
With incresing severity of symptoms on day 2, we
planned to transfuse CCP 200 mL per day for consecutive two days as per
the hospital COVID-19 management protocol. Both CCP doses contained
antibodies against SARS-CoV-2 IgG at a titre of 1:640 (S/Co = 5.1). Due
to a decreasing hemoglobin of 7.3 g/dL with high FiO2 of 80% requirement
on day 3, we transfused one unit (250 mL) leuko-depleted packed red
blood cells (PRBC) each on day 3 and day 4. Between day 4 and 6, we were
able to taper-off the inotropes. The child responded to the CCP therapy
and from day 5 improvement of clinical features and laboratory values
were noted. She was weaned off from mechanical ventilation to room air
by day 7, alongwith improvement in hematological, biochemical and
inflammatory markers. Remdesivir was continued for 10 days in view of
critical COVID-19. Repeat echocardiography suggested normal cardiac
function. Child was discharged on day 10 on tapering oral prednisolone
for 14 days. Child is doing well with no squelae and currently on no
medication except nutritional rehabilitation.
Presenting with classic symptoms of COVID-19, our
patient deteriorated rapidly and developed septicemia and progressed to
septic shock despite initiating standard therapy. Deranged
haematological, biochemical and inflammatory markers with changing X-ray
findings in the child were likely to be associated with increased
severity or worse outcomes of COVID-19. Such association in adults has
also been demons-trated by previous authors [7]. The treatment of severe
COVID-19 in children is close monitoring and supportive care. Antiviral
or adjunctive therapy is a suggestion for selected patients in clinical
trials [4]. Figlerowicz, et al. [5] from Poland reported a 6-year-old
girl with severe COVID-19, in whom SARS-CoV-2 was successfully
eliminated after convalescent plasma transfusion. As our primary goal
was to retard the disease process, improve the clinical features, and
save the child, we considered transfusion of CCP in recommended doses,
which not only improved the clinical features and laboratory findings,
but also helped complete recovery of the child within 10 days of
admission in the hospital.
We conclude that complete information on clinical
manifestations of COVID-19 in children and appropriate management are
still evolving. Thus, individualization of COVID-19 treatment must be
considered, depending on clinical features, laboratory findings and
severity. CCP transfusion in children has the potential to slow down the
COVID-19 disease process and improve clinical manifestations of rapidly.
REFERENCES
1. Meena J, Yadav J, Saini L, Yadav A, Kumar J.
Clinical Features and Outcome of SARS-CoV-2 Infection in Children: A
Systematic Review and Meta-analysis. Indian Pediatr. 2020;57:820-26.
2. Zimmermann P, Curtis N. Coronavirus infection in
children including COVID-19: an overview of the epidemiology, clinical
features, diagnosis, treatment and prevention option in children. Pediatr
Infect Dis J. 2020;39:355-68.
3. Chiotos K, Bassiri H, Behrens E, et al.
Multisystem inflammatory syndrome in children during the COVID-19
pandemic: A case series. J Pediatric Infect Dis Soc. 2020;9:393-98
4. Ye Z, Rochwerg B, Wang Y, et al. Treatment of
patients with nonsevere and severe coronavirus disease 2019: An
evidence-based guideline. CMAJ. 2020;192:E536-41.
5. Figlerowicz M, Mania A, Lubarski K, et al. First
case of convalescent plasma transfusion in a child with
COVID-19-associated severe aplastic anemia. Transfus Apher Sci. 2020;
102866
6. Duan K, Liu B, Li C, et al. Effectiveness of
convalescent plasmatherapy in severe COVID-19 patients. Proc Natl Acad
Sci USA. 2020;117:9490-96.
7. Velavan TP, Meyer CG. Mild versus severe COVID-19:
Laboratory markers. Int J Infect Dis. 2020;95:304-07.
|
|
 |
|